CCND1 and idiopathic pulmonary fibrosis: Accordingly, our study explores for the first time expression levels of cyclin D1 in IPF patient-derived fibroblasts (and equivalent controls) and identifies the influence of Rho, using constitutively active and dominant negative RhoA constructs as well as pharmacological inhibitors, including the agent Simvastatin.